|Place of Origin:||CHINA|
|Certification:||GMP , ISO 9001:2008|
|Minimum Order Quantity:||10g|
|Packaging Details:||Disguised Package|
|Delivery Time:||2 Working Days|
|Payment Terms:||Bank Transfer - Bitcoin - Western Union - MoneyGram|
|Supply Ability:||100 KG/Month|
|Appearance:||White Powder||Usage:||Treatment Of Parkinson's Disease|
|Shipping Method:||EMS, HKEMS, FEDEX, DHL, UPS, Aramex, ETC||Color:||White|
pharmaceutical active ingredients,
pharmaceutical fine chemicals
|Synonyms||(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole Dihydrochloride Monohydrate; Pramipexole dihydrochloride; Pramipexole dihydroch;
(S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride PPX dihydrochloride; Pramipexole; Pramipexole 2HCl Monohydrate;Pramipexole Dihydrochloride Monohydrate;
|Appearance||white to off-white crystalline powder|
|Boiling Point||378ºC at 760 mmHg|
|Vapor Pressure||9.93E-11mmHg at 25°C|
Parkinson’s disease is a common chronic progressive neurodegenerative disease among middle-aged and elderly people, that dopaminergic neurodegeneration in the substantia nigra compacta results in obvious reduction of dopaminergic neurotransmitters on the striatonigral degeneration pathway. Although levodopa substitution therapy can improve I clinical symptoms at the initial stage of Parkinson’s disease effectively, its long-term use results in the recession of curative effect and some complications, such as motor fluctuation, dyskinesia, mental symptom, etc. The dopamine receptor agonist can overcome the above insufficiencies of levodopa, delay starting time of levodopa treatment and enhance curative effect. In clinic, the drug is mainly applied to treat some signs and symptoms of idiopathic Parkinson’s disease, separately-used (no levodopa) or jointly-used (with levodopa). For example, with wearing-off, change or fluctuation (end of dose phenomenon or “on-off” fluctuation) of levodopa’s curative effect at the later stage, the drug shall be applied.
Pramipexole (Mirapex, Mirapexin, Sifrol) is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Pramipexole has some of the same effects as a chemical called dopamine, which occurs naturally in your body. Low levels of dopamine in the brain are associated with Parkinson's disease.Only immediate-release pramipexole (Mirapex) is approved to treat either Parkinson symptoms or RLS. Extended-release pramipexole (Mirapex ER) is approved only to treat Parkinson symptoms.In a single controlled study of twenty one patients, pramipexole was found to be highly effective in the treatment of bipolar depression. Treatment was initiated at 0.125 mg three times a day and increased at a rate of 0.125 mg three times a day to a limit of 4.5 mg daily until the patients' condition satisfactorily responded to the medication or they could not abide the side effects. The final average dosage was 1.7 ± 0.9 mg daily.
1. Pramipexole is a dopamine agonist that directly correlates with the prolactin hormone. As dopamine levels in the body go up, prolactin levels go down. It does this by having a direct effect on the dopamine D3 receptor. Although it also acts on the D2 receptor its affinity for the D3 receptor is seven times greater than any existing dopamine agonist.
2. The effect of Pramipexole on the D3 receptor has a strong impact on the neurological system, which is why it’s used to treat Parkinson’s disease and in some cases Alzheimer’s disease.
3. Through acting on the D3 receptor, Pramipexole also affects a man’s sexual interest and activity. Prolactin is in part directly responsible for a man’s refractory period, which refers to the time it takes to recover from sexual activity so that performance can occur again.
4. By lowering prolactin through an increase in dopamine, Pramipexole can directly reduce the refractory period resulting in the ability to perform sexually more frequently.